Hepatitis B surface antigen (HBsAg) seroclearance in chronic HBV infection occurs at an annual incidence of 1-2%. The long-term outcome after HBsAg seroclearance is excellent if there is no pre-existing cirrhosis or viral superinfection. For this reason, HBsAg seroclearance has attracted recent interest in both long-term studies of the natural history of HBV infection and in patients receiving antiviral therapy. Here, we review a diverse range of studies investigating spontaneous HBsAg seroclearance in varied groups of patients and consider the many predictive factors -of both viral and host origin -for seroclearance. Studies to assess the effects of antiviral therapy, and in particular interferon treatment, are also discussed together with virological, biochemical and histological profiles following HBsAg seroclearance and the long-term outcomes.
The natural course of chronic HBV infection comprises three chronological phases: an initial immune tolerant phase during which patients are positive for hepatitis B virus e antigen (HBeAg) and have normal alanine aminotransferase (ALT) levels; an immune clearance phase when HBeAg-positive patients encounter ALT increases; and a final phase when HBeAg undergoes seroconversion to its antibody and ALT levels normalize, marking the transition to the inactive residual phase [1] . Although up to 30% of these so-called inactive hepatitis B surface antigen (HBsAg) carriers might encounter HBV reactivation and develop HBeAgnegative chronic hepatitis, most inactive carriers remain stably inactive in a lifetime [2, 3] and some eventually clear HBsAg from serum [1, 4] .
Spontaneous HBsAg seroclearance, defined as the loss of serum HBsAg on two occasions at least 6 months apart and remaining absent up to the last visit [4] , is a rare event in the natural history of chronic HBV infection. On the basis of earlier observations (reported before the 1990s), it was suggested that delayed HBsAg seroclearance was more common in Caucasian HBsAg carriers than in Asian HBsAg carriers [5] . It is of note that the follow-up duration in these earlier studies was relatively short; studies from our unit showed a higher incidence of HBsAg seroclearance when the mean follow-up period was extended from 2.7 [4] to 10.8 years [6] . Recently, HBsAg seroclearance has attracted increasing attention both in long-term studies on the natural history of HBV infection and in patients who received antiviral therapy. Thus, it is timely to review and further analyse the issues surrounding HBsAg seroclearance during the natural course of infection or after antiviral therapy.
Incidence of spontaneous HBsAg seroclearance
The incidence of spontaneous HBsAg seroclearance has been calculated in many cohorts of patients with chronic HBV infection in both Western and Eastern countries. As summarized in Table 1 , the characteristics of these study cohorts varied widely, including asymptomatic HBsAg carriers with normal ALT levels [4] , inactive HBsAg carriers [6] , HBsAg carriers identified during screening or upon blood donation [7] [8] [9] [10] [11] [12] [13] , chronic hepatitis B patients with or without cirrhosis [4, [14] [15] [16] [17] and only patients with cirrhosis [18, 19] . There was also a remarkable difference in patient age at enrolment, gender, serum HBeAg status and duration of follow-up among these studies. As shown in Table 1 , the annual incidence of HBsAg seroclearance did not differ much between Caucasian and Asian cohorts. The annual incidence of HBsAg seroclearance varied from 0.12 to 2.38% in cohorts from Asian countries [4, 6, 9, 10, 15, 19] and from 0.54 to 1.98% in cohorts from Western countries [7, 8, [11] [12] [13] [16] [17] [18] .
Introduction
The incidence was only 0.8% per year in European cirrhotic patients whose onset of cirrhosis was unknown [18] , whereas it was 1.5% per year in Taiwanese patients with newly developed cirrhosis [19] .
Our recent study of 1,965 inactive HBsAg carriers from Taiwan showed that HBsAg seroclearance occurred at an average rate of 1.15% per year. It is of note that the cumulative probability of HBsAg seroclearance was 8.1% after 10 years, but increased disproportionately to 24.9% and 44.7% at 20 and 25 years follow-up, respectively [6] . These data suggest that HBsAg seroclearance might accelerate upon longer (>10 years) follow-up. The low HBsAg seroclearance rates reported in earlier studies might be due to the relatively short period of follow-up (Table 1) .
Predictive factors for spontaneous HBsAg seroclearance
Several viral and host factors have been shown to have a significant association with HBsAg seroclearance in cohort or case-control studies, as summarized in Table 2 .
Host factors
Age One of the most important factors for HBsAg seroclearance appears to be the older age of patients at enrolment, which has been demonstrated in many studies [4, 6, [8] [9] [10] 12, 13, 15, 17, 20] . For example, our study in 1,965 inactive carriers showed that the annual incidence of HBsAg seroclearance was 0.77% per year for individuals aged <30 years and rose to 1.07%, 1.65% and 1.83% per year in individuals aged 30-39 years, 40-49 years and ≥50 years, respectively, at enrolment [6] . Among the cohorts listed in Table 1 [4, [6] [7] [8] [9] [10] [11] [12] [13] [15] [16] [17] , excluding the studies in patients with cirrhosis at the time of HBsAg seroclearance [18, 19] , the annual incidence of HBsAg seroclearance of each study correlated significantly with the mean or median age of patients at enrolment of each cohort (Figure 1) . Conceivably, the probability of HBsAg seroclearance increases along 
• Older age [4, 6, [8] [9] [10] 12, 13, 15, 17, 20] • Gender: female>male [8] , male>female [6] • Normal alanine aminotransferease levels at baseline [4, 15] • Inactive carrier state>reactivation of hepatitis B [6] • Fatty liver [27, 28] • Cirrhosis at baseline [17] or development during follow-up [4] 
Viral factors
• HBeAg negativity at baseline [4, 12, 15] • Hepatitis B virus DNA negativity by hybridization at baseline [15] • Genotype: B>C [31] , A>D [17] • Hepatitis C virus superinfection [20, 38] with the duration of infection, as reflected in the age of patients. This is particularly true in countries where HBV infection occurs predominantly during the perinatal period or early childhood; thus, the age of the patient is virtually equivalent to the duration of infection. In view of this observation, it is not unexpected that HBsAg seroclearance is relatively uncommon in carrier children under 10 years of age. In a cohort of 420 children from Taiwan (<1 month to 17 years of age), HBsAg seroclearance occurred in 10 children during a mean follow-up period of 4.3 years: the age at HBsAg seroclearance was <10 years in only three, 10-20 years in six and >20 years in one [21] . By contrast, as summarized in Table 3 , the mean or median age of HBsAg seroclearance in several series reported from Asian countries, including Korea [22] , Japan [9, 23] , Hong Kong [24] and Taiwan [6] , was approximately 50 years (range: 48-54 years). Figure 2A shows the distribution of age at HBsAg seroclearance and Figure 2B shows the box plot of the age at HBsAg seroclearance in our 245 carriers from Taiwan [6] . The peak age distribution was 50-55 years and 104 (42.4%) patients lost serum HBsAg between 46 and 54 years of age. Moreover, 25%, 50% and 75% of patients cleared HBsAg at ages 41, 48 and 53 years, respectively. These data indicate that HBsAg seroclearance typically occurs after 40-50 years of infection in HBsAg carriers who acquired chronic HBV infection perinatally or during early childhood. Given these age ranges, together with the fact that the mean or median age of HBeAg seroconversion in the Asian carriers ranged from 30 to 35 years [1] , it can be calculated that sustained remission for a mean of 15 years is required to achieve subsequent HBsAg seroclearance in inactive carriers.
Gender
Most studies did not recognise gender difference in the incidence of HBsAg seroclearance, with the exception of two studies from Alaska and Taiwan. In the study from Alaska, female carriers were found to be more likely to clear HBsAg than males [8] . By contrast, a study from Taiwan showed that HBsAg seroclearance was significantly more common in male carriers in a univariate analysis, although the difference became marginally significant in multivariate analysis [6] . The reason for the discrepancies between these two studies remains unclear, but the Alaskan study involved smaller numbers of patients (218 versus 1,965), HBsAg carriers of younger age (20.9 versus 35.6 years), much higher HBeAg positive rates (69 versus 0%) and shorter follow-up (6.1 versus 10.8 years).
Alanine aminotransferase levels
HBsAg carriers who were positive for antibody against HBeAg (anti-HBe) and exhibited normal ALT levels at enrolment were more likely to clear HBsAg than those with abnormal ALT levels [4, 15] . Similarly, inactive carriers with sustained biochemical remission were more likely to clear serum HBsAg than those with reactivation of hepatitis B [6] . These data are consistent with the postulation that HBsAg seroclearance is usually preceded by a long period of sustained remission in inactive carriers. 
Cirrhosis
Cirrhosis at baseline or developed during follow-up was shown to be significantly associated with HBsAg seroclearance [4, 17] . Indeed, the incidence of HBsAg seroclearance in our cohort with newly developed cirrhosis seems higher than that in our non-cirrhotic cohort (1.5 versus 1.2% per year) [6, 19] . However, seroclearance was not higher in a European cohort of patients with compensated cirrhosis [18] , possibly because the follow-up period of this latter study was too short. These patients might be recognized as having cryptogenic cirrhosis if the prior HBsAg carrier state had never been previously identified. The underlying mechanism remains unclear. Increased seroclearance in the presence of cirrhosis could reflect either the absence or partial expression of HBV genomes in the liver, a status that might have developed in cirrhotic patients [25, 26] . Whether or not increased liver cell turnover as a result of liver regeneration might enhance HBsAg seroclearance needs further investigation.
Fatty metamorphosis of liver
Moderate or severe hepatic steatosis has been shown to contribute to HBsAg seroclearance in our case-control and cohort studies [27, 28] . There is widespread expression of HBsAg in hepatocyte cytoplasm in inactive carriers [29] . Substantial amounts of fatty infiltration in the liver could interfere with the cytoplasmic expression of HBsAg and thus contribute to HBsAg seroclearance in chronic HBV infection. Alternatively, the Fas receptor is strongly expressed in hepatocytes from patients with non-alcoholic steatohepatitis and might lead to an increased susceptibility of these cells to apoptosis, thus facilitating clearance of the virus [30] .
Viral factors
HBeAg or HBV DNA negativity by hybridization assay HBsAg carriers who are negative for HBeAg [4, 12, 15] or negative for HBV DNA by hybridization assay [15] are more likely to be at the later inactive phase of chronic HBV infection, and thus more likely to clear HBsAg from serum. It is conceivable that patients with less active HBV replication are more likely to have disease remission and hence HBsAg seroclearance.
Genotype A higher prevalence of genotype B HBV infection (than genotype C) was found in carriers with HBsAg seroclearance in a case-control study conducted in Hong Kong [31] . Studies in Taiwan have demonstrated that genotype B HBV infection is associated with a higher rate and younger age of HBeAg seroconversion [32] , and a lower rate of reactivation of hepatitis B [32, 33] than genotype C HBV infection. Conceivably, HBsAg seroclearance is more likely in genotype B HBV infection than in genotype C. In one study conducted in Spain, genotype A HBV infection was found to have a significantly higher rate of sustained biochemical remission, as well as HBsAg seroclearance, when compared with genotype D HBV infection [17] .
Serotype
In a study from Okinawa, Japan, in addition to older age at enrolment, carriers with HBsAg serotype adr were 2.87× more likely to clear HBsAg than carriers with serotype adw. However, in that study, carriers with serotype adw had a marginally (P=0.06) higher rate of HBeAg seroconversion than those with serotype adr [9] . The reason for the discrepancies between HBeAg seroconversion and HBsAg seroclearance remains unclear.
Viral superinfection
In several sporadic case reports, acute superinfection with hepatitis A virus (HAV), HCV or hepatitis D virus (HDV) in chronic HBsAg carriers was followed by a transient or persistent loss of HBsAg with seroconversion to antibody against HBsAg (anti-HBs) [34] [35] [36] . In one study from Italy, HBsAg carriers with HDV superinfection were found to be more likely to clear HBsAg than those without [37] . However, our multivariate analyses showed that HDV superinfection was not a factor for spontaneous HBsAg seroclearance [4, 20] . By contrast, HBsAg carriers with HCV superinfection were found to be significantly more likely to clear HBsAg than HBsAg carriers with HDV superinfection or HBV monoinfection [20] . As the onset and duration of viral superinfection in most of these studies were unknown, the impact of the duration of superinfection on the different effects of HDV and HCV superinfection was unknown. In a recent study involving patients with well-defined onset of superinfection, the cumulative probability of HBsAg seroclearance was 14% at 10 years after the onset of acute HCV infection, 9% after the onset of acute HDV infection and 4% in an age/sex-matched control group of chronic HBV monoinfection. A significant difference was found only between HCV and HBV groups [38] . These results also indicated that HBsAg seroclearance occurred earlier and more frequently in HCV superinfection than HDV superinfection.
Therapy-induced HBsAg seroclearance
Interferon-based therapy has been shown to induce HBsAg seroclearance in a substantial proportion of patients with HBeAg-positive [39] [40] [41] [42] [43] [44] [45] or HBeAgnegative chronic hepatitis [46, 47] from Western countries. Between 13% and 27% of patients treated with conventional interferon (IFN) cleared HBsAg from serum during a mean follow-up period of 3.4-6.2 years with an estimated annual rate of 2.6-4.4% [39] [40] [41] [42] [43] 47] . By contrast, IFN-induced HBsAg seroclearance was much lower in Asian patients. In an earlier study from Hong Kong, only 2 of 128 HBeAg-positive patients with chronic hepatitis treated with IFN cleared HBsAg from serum during a mean follow-up of 3.4 years with an estimated annual incidence of 0.46% [48] . A further study from Hong Kong involving 208 HBeAg-positive patients showed HBsAg seroclearance in only seven (3.3%) during a median follow-up of 107 months after IFN therapy [49] . Likewise, a study from Taiwan showed that only 7 (3%) of 233 HBeAg-positive patients with chronic hepatitis lost HBsAg during a median follow-up of 8.8 years after IFN therapy [50] . Nevertheless, therapeutically induced termination of the HBsAg carrier state should be judged against the background of spontaneous HBsAg seroclearance. In several non-randomized controlled studies, the HBsAg seroclearance rates of IFN-treated patients were compared with the controls without treatment (Table 4) . Among 6 studies from Western countries, including 5 studies in HBeAg-positive chronic hepatitis [42, [51] [52] [53] [54] and 1 study in HBeAg-negative chronic hepatitis [55] [49, 50] . The mean annual rate of HBsAg seroclearance was 0.43% per year in IFN-treated patients versus 0.07% per year in untreated controls. IFN treatment was associated with a 6.63-fold increased likelihood of HBsAg seroclearance (95% CI 1.84-23.91; P=0.0038). The reason for the substantially lower rate of HBsAg seroclearance in the Asian studies is unknown. As mentioned before, sustained remission for a mean period of 15 years is required to achieve subsequent HBsAg seroclearance in the Asian inactive carriers; further follow-up might see a higher HBsAg seroclearance rate.
A study involving HBeAg-positive patients showed that 19 (11%) of 172 patients treated with pegylated interferon (PEG-IFN)-a2b (alone or combined with lamivudine) lost serum HBsAg 3 years post-treatment, whereas none of the patients treated with lamivudine alone lost serum HBsAg. Moreover, 19 (30%) of the 64 PEG-IFN initial responders (that is, patients with HBeAg loss at 26 weeks post-treatment) cleared HBsAg with a 4 year cumulative probability of 29%, whereas none of the initial non-responders cleared HBsAg. In addition, HBsAg seroclearance occurred significantly more often in patients with genotype A HBV infection than in those with genotype non-A HBV infection [44] . In another study involving HBeAg-negative patients, 20 (8.7%) of 230 patients treated with PEG-IFN-a2a (alone or combined with lamivudine) cleared HBsAg 3 years after the end of treatment, whereas none of the patients treated with lamivudine alone showed clearance. HBsAg seroclearance did not appear to be genotype-related in HBeAg-negative patients treated with PEG-IFN-a2a, although the rate looked higher in genotype A-infected patients (20% versus 6-9% in non-A genotypes) [46] . The study showed that HBsAg seroclearance at 3 years post-treatment was observed more frequently in patients who had HBV DNA ≤400 copies/ ml at the end of treatment (17 [9. 4%] of the 181 versus 1 [2%] of the 49 patients with HBV DNA >400 copies/ml). Among those with undetectable HBV DNA at 3 years post-treatment, HBsAg seroclearance occurred in up to 44% [46] . Further study showed a significant decline in HBsAg level during treatment with PEG-IFN-a2a, but not during treatment with lamivudine alone, and significantly more patients treated with PEG-IFN-a2a achieved HBsAg levels <100 IU/ml at the end of treatment compared with lamivudine alone [56] . Another study showed that a decrease of 0.5 and 1 log 10 IU/ml in serum HBsAg levels at weeks 12 and 24 of PEG-IFN-a2a therapy, respectively, correlated with sustained virological response. In addition, an HBsAg level <10 IU/ml at week 48 and on-treatment decline >1 log 10 IU/ml correlated significantly with HBsAg seroclearance at 3 years post-treatment [57] .
HBsAg seroclearance is very rare following 1-2 years of therapy with nucleos(t)ide analogues [44, 46] . One exception has been reported in treatment with tenofovir, where seroclearance rates of 3% and 6% were observed after 1 and 2 years therapy, respectively, in HBeAg-positive patients with chronic hepatitis B; however, seroclearance was not seen in HBeAg-negative patients [58, 59] . HBsAg seroclearance was documented in 2% of 171 HBeAg-positive and 5% of 125 HBeAgnegative patients treated with adefovir up to 5 years [60, 61] and in 18 (5%) of 354 HBeAg-positive patients on entecavir therapy for up to 96 weeks [62] . It remains to be seen whether such HBsAg seroclearance is similar to that observed after lamivudine therapy, which might be caused by a point mutation in the S gene resulting in detection failure [63] .
It has been shown that therapy with nucleos(t)ide analogues alone or in combination with PEG-IFN reduced levels of intrahepatic covalently closed circular DNA (cccDNA), which correlated with a decline in serum HBsAg titres [64] [65] [66] [67] . A 48-week treatment with adefovir dipivoxil, lamivudine or entecavir reduced 0.8-1.0 log 10 cccDNA levels by a primarily non-cytolytic mechanism [64, 65] . Nevertheless, it is possible that the extent of cccDNA decline is still insufficient to induce HBsAg seroclearance in most of the nucleos(t)ide analogue-treated patients. However, PEG-IFN-a2b plus adefovir for 48 weeks, resulted in a strong cccDNA decline of 2.4 log 10 ; the number of hepatocytes positive for HBsAg and hepatitis B core antigen (HBcAg) was significantly lower after treatment, suggesting the involvement of cytolytic mechanisms [66] . These data highlight the immunomodulatory effects of IFN in HBsAg seroclearance as a result of immune control.
Virological, biochemical and histological profiles following HBsAg seroclearance
In general, up to 80% of patients with HBsAg seroclearance had detectable anti-HBs after HBsAg seroclearance [4, 9, 13, [22] [23] [24] . As summarized in Table 5 , only 17% of the carriers had detectable anti-HBs within 1 year after HBsAg seroclearance [24] , but the proportion of carriers positive for anti-HBs increased to 56% at the fifth year and 76% at the tenth year following HBsAg seroclearance [23] . At the time of HBsAg seroclearance, virtually all carriers became negative for HBV DNA as measured by hybridization assay, but 30-70% were still positive for HBV DNA as measured by PCR-based assay [68, 69] . The proportion of carriers with detectable HBV DNA as measured by PCR-based assay then decreased to 10-20% between 5 and 10 years [24, 69] and to <10% over 10 years after HBsAg seroclearance [24] (Table 5) . Despite the extremely low viraemic state, 5-18% of carriers had abnormal ALT levels after HBsAg seroclearance [4, 9, 23, 24, 69] . However, non-HBV-related etiologies of abnormal ALT levels can be identified in 75-100% of such cases, with fatty liver and alcoholism being the most common causes [9, 23, 24, 69] . In addition, HCV might have displaced HBV to cause continuing ALT increase and hepatitis activity [4, 38, 70] . Notably, in the Hong Kong cohort, herbal medicine administration accounted for 26.3% (10/38) of cases with abnormal ALT levels following HBsAg seroclearance [24] .
Most of the patients with liver histological assessment showed mild necroinflammation and no significant fibrosis. Immunostaining for HBsAg and HBcAg was negative in all patients [4, [22] [23] [24] ; however, all patients tested still harboured HBV inside the liver (mainly in the form of cccDNA) up to 4 years after HBsAg seroclearance, albeit at a very low replicative level and in a transcriptionally inactive phase [22, 24, 64, 68] . This so-called 'occult HBV infection' can account for the reactivation of hepatitis B in patients receiving immunosuppressants or chemotherapy after loss of HBsAg [71] .
Long-term outcomes after HBsAg seroclearance
In addition to a remarkable decrease or loss of all serum markers of HBV replication and gain of anti-HBs over time, most patients with HBsAg seroclearance have an excellent outcome; patients are at a state closest to a 'cure' if there is no pre-existing cirrhosis or HCV and/or HDV superinfection [23, 72] . A few studies showed that the risk of hepatic decompensation and/or hepatocellular carcinoma (HCC) development did not decrease as compared with patients without HBsAg seroclearance [24, 73] ; however, further analysis of these studies revealed that most patients had HCV superinfection or had developed cirrhosis before HBsAg seroclearance [72, 74] . Table 6 summarizes the long-term outcome after HBsAg seroclearance in relation to viral superinfection and pre-existing cirrhosis at the time of HBsAg seroclearance in reported studies.
The unusual findings reported in two studies deserve further discussion. In the study by Yuen et al. [24] , the high incidence of HCC and hepatic decompensation could be the result of pre-existing cirrhosis and inadequate HCC surveillance [74] . In the study by Huo et al. [4] et al. [68] et al. [9] et al. [13] et al. [22] et al. [23] et al. [24] et al. [69] Number [73], the mean age of their 55 carriers with HBsAg seroclearance was 54 years, 20 had viral superinfection but none had cirrhosis at the time of HBsAg seroclearance. However, during a mean follow-up of 23 months, 18 (including 6 with viral superinfection) had adverse outcomes (cirrhosis in 6, HCC in 11 and hepatic failure in 1). As 7 of 9 HCC cases had proven concomitant cirrhosis during operation, a total of at least 13 new cirrhosis cases were identified, giving an incidence of cirrhosis as 12% per year. Furthermore, 7 of the 13 newly diagnosed cirrhosis cases developed HCC during the very short mean follow-up. Both figures are unusually high and were even worse than those in patients with persistent HBeAg seropositivity [50] . Totally different results were reported in two subsequent studies by Chen et al. [72] and Arase et al. [23] , which involved much larger numbers of patients with spontaneous HBsAg seroclearance. In these 2 studies none of the patients developed cirrhosis or HCC during a mean follow-up period of about 5 years in their respective 146 and 164 carriers without evidence of cirrhosis or viral superinfection at the time of HBsAg seroclearance. Moreover, of the 43 carriers with viral superinfection in Chen's series, only three developed cirrhosis during a mean follow-up of 65 months (or at an annual rate of 1.3%) [72] . The results of these two large series studies with longer periods of follow-up might more reliably reflect the excellent outcomes following HBsAg seroclearance. Given such excellent prognosis, it was suggested that the follow-up interval might be extended to once a year in those without evidence of cirrhosis or HCV superinfection at the time of HBsAg seroclearance [72] . Among carriers with cirrhosis at the time of HBsAg seroclearance who had no evidence of viral superinfection, liver function can improve or remain stable [75] and hepatic decompensation rarely occurred [18, 72] . However, the incidence of HCC varied remarkably in the different reported series. HCC developed in none of the 17 patients in Chen's series [72] , none of 27 patients in Fattovich's series [18] , none of the 19 patients in Moucari's series [45] , in only 2 (3%) of 67 patients in Arase's series [23] , but in 4 (24%) of 17 patients in Ahn's series [22] and 4 (31%) of 13 patients in Tong's series [76] . The reasons for these discrepancies remain unclear. The mean age at HBsAg seroclearance did not differ much among these series (Table 6) . Notably, three of four HCC cases in Tong's series had a family history of HCC [76] . It has been shown that a family history of HCC increases the risk of HCC development in HBsAg carriers by 2.41-5.35 times [77] . Whether this factor could account for HCC development after HBsAg seroclearance warrants further studies.
Conclusion and perspectives
The incidence of HBsAg seroclearance varies considerably in different reported series at an annual incidence of 1-2% and does not differ much between Caucasian and Asian carriers. A long-term (>15 years) inactive carrier state is usually required to achieve subsequent HBsAg seroclearance. Older age, HBeAg seronegativity, clinical remission and cirrhosis are predictive factors for HBsAg seroclearance. Age of the patient or duration of chronic HBV infection acquired in early life appear to be the most significant and constant determining factor associated with HBsAg seroclearance. IFN treatment for chronic hepatitis B has been shown to enhance HBsAg seroclearance by approximately threefold in Western studies and sixfold in Asian studies. HBsAg seroclearance is almost always associated with loss of all serum markers of HBV replication, including HBV DNA as identified by PCR methods, and gain of anti-HBs over time. The long-term outcome following HBsAg seroclearance is excellent if there is no pre-existing cirrhosis or viral superinfection. It seems appropriate to assay HBsAg every 2-3 years to detect HBsAg seroclearance in HBeAg-negative HBsAg carriers with sustained remission, especially in those with cirrhosis. In non-cirrhotic patients who have no evidence of HCV superinfection, the follow-up interval may be extended to once per year after HBsAg seroclearance. Hepatic decompensation becomes extremely rare after HBsAg seroclearance, even in patients with pre-existing cirrhosis who have no evidence of viral superinfection; however, these cirrhotic patients are still at risk of HCC and therefore still require surveillance at least every 6 months. In this regard, critical assessment is needed to rule out the existence of cirrhosis or HCV superinfection in patients who have undergone HBsAg seroclearance.
